Country: Malta
Language: English
Source: Medicines Authority
Sumar Pharma ehf Haukahlijð 5 102 Reykjavik, Iceland
H01BA02
DESMOPRESSIN 60 µg
SUBLINGUAL TABLET
DESMOPRESSIN 60 µg
POM
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
Authorised
2023-01-16
Page 1 of 6 PACKAGE LEAFLET: INFORMATION FOR THE USER DESMOPRESSIN SUMAR 60 MICROGRAMS SUBLINGUAL TABLETS DESMOPRESSIN SUMAR 120 MICROGRAMS SUBLINGUAL TABLETS DESMOPRESSIN SUMAR 240 MICROGRAMS SUBLINGUAL TABLETS desmopressin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Desmopressin Sumar is and what it is used for 2. What you need to know before you take Desmopressin Sumar 3. How to take Desmopressin Sumar 4. Possible side effects 5. How to store Desmopressin Sumar 6. Contents of the pack and other information 1. WHAT DESMOPRESSIN SUMAR IS AND WHAT IT IS USED FOR Desmopressin, the active substance in Desmopressin Sumar acts like the natural hormone vasopressin and regulates the kidneys' ability to concentrate urine. Desmopressin Sumar is used to treat: - Central diabetes insipidus (pituitary disorder leading to severe thirst and large amounts of urine). - Bed wetting in children from 5 years of age with normal ability to concentrate urine. - Nocturnal urination in adults (night time urine production exceeding bladder capacity). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE DESMOPRESSIN SUMAR _ _ DO NOT TAKE DESMOPRESSIN SUMAR: - if you are allergic to desmopressin or any of the other ingredients of this medicine (listed in section 6) - if you suffer from polydipsia (abnormally high fluid intake) resulting in high volume of urine eliminated in one day (more than 40 ml/kg/24 h) - if you have previous or suspected heart failure or other conditions that require treatment with diuretics (medicines used Read the complete document
Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Desmopressin Sumar 60 micrograms sublingual tablets Desmopressin Sumar 120 micrograms sublingual tablets Desmopressin Sumar 240 micrograms sublingual tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Desmopressin Sumar 60 micrograms sublingual tablet contains 67 micrograms desmopressin acetate equivalent to 60 micrograms desmopressin. Each Desmopressin Sumar 120 micrograms sublingual tablet contains 133 micrograms desmopressin acetate equivalent to 120 micrograms desmopressin. Each Desmopressin Sumar 240 micrograms sublingual tablet contains 267 micrograms desmopressin acetate equivalent to 240 micrograms desmopressin. Excipient with known effect _Desmopressin Sumar 60 micrograms _ Each sublingual tablet contains 65.23 mg lactose monohydrate. _Desmopressin Sumar 120 micrograms _ Each sublingual tablet contains 65.18 mg lactose monohydrate. _Desmopressin Sumar 240 micrograms _ Each sublingual tablet contains 65.08 mg lactose monohydrate. For a full list of excipients see section 6.1. 3. PHARMACEUTICAL FORM Sublingual tablet Desmopressin Sumar 60 micrograms sublingual tablet White or almost white, round, biconvex tablet debossed with ‘I’ on one side and plain on other side, with 6.5 mm diameter and 2 mm thickness. Desmopressin Sumar 120 micrograms sublingual tablet White or almost white, octagonal, biconvex tablet debossed with ‘II’ on one side and plain on other side, with 6.5 mm length/ width and 2 mm thickness. Desmopressin Sumar 240 micrograms sublingual tablet White or almost white, square, biconvex tablet debossed with ‘III’ on one side and plain on other side, with 6 mm length/ width and 2 mm thickness. Page 2 of 11 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS - Treatment of central diabetes insipidus. - Treatment of primary nocturnal enuresis in patients (from 5 years of age) with a normal ability to concentrate urine. - Symptomatic treatment of nocturia in adults, associated with nocturnal polyuria, i Read the complete document